A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

Study summary

The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in participant with advanced or metastatic malignancies.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedEpacadostat and Nivolumab

Plus 2 other study approaches.

Who it may be forMetastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 28, 2022 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?5 U.S. locations

Locations may change over time.

Who runs it?Incyte Corporation

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 1 / Phase 2
Sponsor: Incyte Corporation
Interventions being studied: Drug: Epacadostat; Drug: Nivolumab; Drug: Ipilimumab; Drug: Lirilumab

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Disease setting

Metastatic or stage IV→

Treatment approach

Immunotherapy→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

During Phase 1, participant with locally advanced or metastatic solid tumors with disease progression on or after treatment with available therapies, or who are intolerant to treatment, or who refuse standard treatment.
During Phase 2, participant with advanced cancer who have received at least one prior therapy or are treatment naive, depending on the specified tumor type.
Presence of measurable disease per RECIST v1.1.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Expected survival of ≥ 12 weeks.

Reasons someone may not be able to joinExclusion criteria

Laboratory and medical history parameters not within the Protocol-defined range.
Receipt of anticancer medications or investigational drugs within Protocol-defined time frames.
Previous radiotherapy within 7 days of Cycle 1 Day 1.
Known active central nervous system metastases and/or carcinomatous meningitis.
Prior treatment with any immune checkpoint inhibitor and/or an IDO inhibitor.
Active infection requiring systemic therapy.
Any active or inactive autoimmune disease or syndrome

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

University of Alabama at BirminghamBirmingham, Alabama
The Angeles Clinic and Research InstituteLos Angeles, California
John Wayne Cancer InstituteSanta Monica, California
Duke University Medical CenterDurham, North Carolina
Vanderbilt University Medical CenterNashville, Tennessee

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 28, 2022. Always confirm current availability with the study team.

View original record ↗